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Abstract 
Stratified medicine utilises individual-level covariates that are associated with a differential 
treatment effect, i.e. treatment-covariate interactions. When multiple trials are available, 
meta-analysis is used to help detect true treatment-covariate interactions by combining their 
data. Meta-regression of trial-level information is prone to low power and ecological bias, 
and therefore individual participant data (IPD) meta-analyses are preferable to examine 
interactions utilising individual-level information. However, one-stage IPD models are often 
wrongly specified, such that interactions are based on amalgamating within- and across-trial 
information. We compare, through simulations and an applied example, fixed-effect and 
random-effects models for a one-stage IPD meta-analysis of time-to-event data where the 
goal is to estimate a treatment-covariate interaction. We show that it is crucial to centre 
patient-level covariates by their mean value in each trial, in order to separate out within-trial 
and across-trial information. Otherwise, bias and coverage of interaction estimates may be 
adversely affected, leading to potentially erroneous conclusions driven by ecological bias. 
We revisit an IPD meta-analysis of 5 epilepsy trials, and examine age as a treatment effect 
modifier. The interaction is -0.011 (95% CI: -0.019 to -0.003; p=0.004), and thus highly 
significant, when amalgamating within-trial and across-trial information. However, when 
separating within-trial from across-trial information the interaction is -0.007 (95% CI: -0.019 
to 0.005; p=0.22), and thus its magnitude and statistical significance are greatly reduced. We 
recommend that meta-analysts should only use within-trial information to examine individual 
predictors of treatment effect, and that one-stage IPD models should separate within- from 
across-trial information to avoid ecological bias. 
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1 Introduction 
There is an increasing interest in personalised or stratified medicine, where the aim is to tailor 
treatments to individuals or to groups of similar individuals based on their particular 
characteristics [1]. This allows clinicians to optimise treatment decisions and reduce 
unnecessary costs, in order to select treatments for individual patients that are most likely to 
benefit (or least likely to harm) them. For example, trastuzumab is only given to the subgroup 
(stratum) of breast cancer patients who are human epidermal growth factor receptor 2 (HER-
2) positive, as it is known to lock on to the HER-2 protein, block the receptor and stop the 
cells from dividing and growing [2]. It is therefore considered unnecessary for those who are 
HER-2 negative. 
 
A key component of stratified medicine research is to identify individual-level characteristics 
(covariates) that are associated with a differential treatment effect [1]. These are referred to as 
treatment-covariate interactions in this article, but other names include effect-modifiers, 
moderators, subgroup effects and predictive markers. Though some treatment-covariate 
interactions, such as HER-2, are suspected in advance due to strong biological rationale, 
others are only identified following secondary investigations of existing data. A single 
randomised trial tends to have low power to detect treatment-covariate interactions because 
usually they are powered on the overall treatment effect in the population of interest [3]. 
However, when multiple trials are available, meta-analysis provides the opportunity to 
increase power to detect true treatment-covariate interactions by combining their data [4]. 
 
In aggregate data (AD) meta-analysis, where aggregated study results are obtained and then 
synthesised, treatment-covariate interactions are usually investigated using meta-regression 
[5], which quantifies the across-studies association between the overall treatment effect and 
aggregated trial-level covariates (such as mean age, proportion male). However, this 
approach usually has low power to identify genuine treatment effect modifiers at the 
4 
individual-level due to the usually small number of studies in meta-analysis [6]; there needs 
to be large variation in the aggregated covariate values across trials for the power to be 
feasible [7]. Further, it is also prone to study-level confounding and “ecological bias”[8], 
which means the observed across-study relationships do not properly reflect the individual-
level relationships within trials. For example, meta-regression may identify that studies with a 
larger proportion of males have a larger overall treatment effect; however, this may be due to 
such studies also having a higher dose of the treatment, and therefore improved effect is due 
to the dose and not being male [9]. 
 
Individual participant data (IPD) meta-analysis can overcome the issues of low power and 
potential ecological bias by examining within-study interactions at the individual-level (rather 
than across-study interactions at the trial-level). Here, the participant-level data are analysed 
in either a two-stage or a one-stage approach in order to summarise the interaction between 
treatment effect and individual covariates [10-13]. The two-stage approach is the most 
straightforward, where firstly the treatment-covariate interactions are estimated in each trial 
separately, and then secondly these are pooled using a traditional (e.g. inverse-variance 
weighted) meta-analysis model. By only pooling within-study information, this approach 
automatically avoids ecological bias [12, 14]; however, the second stage requires one to 
assume study estimates are approximately normally distributed and that their estimated 
variances are known, which is contentious when included studies only have small number of 
patients and/or events [15, 16]. 
 
The alternative one-stage approach analyses all patient-level data from every trial in one step 
whilst accounting for the clustering of patients within studies using a hierarchical model [17-
19]. In contrast to the two-stage approach, one-stage meta-analysis models allow a more 
exact likelihood to be specified and automatically account for the correlations amongst 
parameters [17]. However, when investigating treatment-covariate interactions, it has been 
shown that the one-stage approach does not automatically avoid ecological bias when 
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estimating treatment-covariate interactions; that is, estimation of interaction terms in a one-
stage meta-analysis might merge (amalgamate) both within- and across-trial information [9, 
20, 21]. To avoid potential ecological bias, one needs to separate out within- and across-trial 
interaction effects in the model specification [9, 12, 14, 22, 23], which is also recognised in 
areas outside the meta-analysis field that contain clustering [24-27]. 
 
Though this topic has been previously discussed in the meta-analysis literature, our recent 
experience is that the issue of ecological bias is still being ignored in many applied one-stage 
IPD meta-analyses, especially in the context of time-to-event outcomes. For example, in 2015 
Sahgal et al. perform a one-stage IPD meta-analysis of randomized trials evaluating 
stereotactic radiosurgery (SRS) with or without whole-brain radiation therapy for patients 
presenting with 1 to 4 brain metastases [28]. They conclude that “age was a significant effect 
modifier (P=.04) favoring SRS alone in patients ≤50 years of age”. However, the publication 
does not state that ecological bias was considered or that within-study and across-study 
interactions were separated. 
 
Data sharing is becoming expected in medical research [29] and the number of IPD meta-
analyses is rising [11, 30], many of which aim to identify treatment effect modifiers. New 
protocols are being published each month for IPD meta-analyses, which pre-define their 
statistical analysis plan. For example, van Middelkoop et al [31] provide a protocol for their 
IPD meta-analysis of trials investigating the effectiveness of intra-articular glucocorticoid 
injections in patients with knee or hip osteoarthritis. The authors state they will use a one-
stage model and to examine how pain or inflammation modify treatment effect, they will 
include “an interaction term (pain × treatment or inflammation × treatment)”; however, 
perhaps unknowingly, this will amalgamate within-study and across-study interactions. 
 
A strong message is thus urgently needed: researchers should avoid potential ecological bias 
in their one-stage IPD meta-analyses. The aim of this article is to show how this can be 
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achieved, and to illustrate the consequences of ignoring it through a detailed simulation study 
and an illustrated example for time-to-event outcomes. In particular, we extend the one-stage 
framework of Tudur Smith et al.[32] proposed in this journal, who showed how to examine 
treatment-covariate interactions but did not adjust for ecological bias. Other recent IPD meta-
analysis articles of time-to-event data consider mainly two-stage methods [14, 33, 34], 
evaluate or compare one-stage and two-stage analyses for the overall treatment effect [35, 
36], or focus on estimation techniques [37-39], including parametric approaches [40], for 
modelling baseline risks and overall effects. However, our main focus is on how to 
appropriately estimate treatment-covariate interactions in this context. Fisher et al. provide an 
excellent overview of methods for estimating interactions in meta-analysis [12], with 
illustration including survival examples; however, our work extends this through the detailed 
simulation study across a wide range of scenarios, with a novel example in epilepsy. 
 
The remainder of the article is as follows. Section 2 introduces four key fixed-effect and 
random-effects Cox regression models that can be used to investigate treatment-covariate 
interactions. Section 3 details the methods and results of the simulation study, which includes 
scenarios for both binary and continuous covariates, with and without trial-level confounders. 
The key findings are then illustrated in the context of a real IPD meta-analysis dataset in 
Section 4, and Section 5 concludes with some discussion. 
 
2 Estimation of treatment-covariate interactions in a one-stage IPD meta-
analysis models for time-to-event data 
Consider the IPD meta-analysis of time-to-event data across j = 1 to J trials. Let xij be a 
participant-level covariate of interest, which can be continuous such as age, or binary such as 
sex, and let zij denote whether the ith patient in the jth trial is in the experimental group or in 
the control group (1=Experiment group, 0=Control group). For each patient, we also have 
whether they had the event or were censored, and their event or censoring time. We now 
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introduce four key specifications of a one-stage IPD meta-analysis model, based on Cox 
proportional hazards models. These all specify a separate baseline hazard specification per 
trial (i.e. not necessarily proportional), assume a constant treatment effect over time in each 
trial (i.e. hazard rates for the treatment and control groups are assumed proportional),, and 
either merge or separate within- and across-study treatment-covariate interactions. Of course, 
other specifications are possible (e.g. proportional baseline hazards across trials)), however 
here the main focus is on the specification of the interactions. For a comprehensive 
introduction of the framework of (random-effects) models for Cox regression and meta-
analysis of time-to-event data, we refer the reader elsewhere [32, 35-39, 41]. 
2.1 Merging within-study and across-study interactions 
A simple, but potentially naïve, model that ignores any residual between-study heterogeneity 
and amalgamates within- and across-trial interactions can be written as follows: 
 𝜆𝑖𝑗(𝑡) = 𝜆0𝑗(𝑡)exp⁡(𝛽1𝑧𝑖𝑗 + 𝛽2𝑖𝑥𝑖𝑗 + 𝛽𝑇𝑥𝑖𝑗𝑧𝑖𝑗) (1) 
Here 𝜆0𝑗(𝑡) denotes the unique baseline hazard function in the jth trial  and 𝑥𝑖𝑗𝑧𝑖𝑗  represents 
the interaction term between the treatment and covariate of interest, which is an 
amalgamation of within-study and between-study information. The constant coefficient 𝛽1 is 
the treatment effect (i.e. the change in the log hazard for patients in the treatment group rather 
than control group) where 𝑥𝑖𝑗=0, 𝛽2𝑖  is the study-specific change in the log hazard for a 1-unit 
increase in the patient-level covariate where 𝑧𝑖𝑗=0, and 𝛽𝑇  denotes the additional change in 
the log hazard for patients in the new treatment group compared with the control group for 
one unit increasing values of 𝑥𝑖𝑗. We note that the separate baseline hazard per trial (𝜆0𝑗(𝑡)) 
is essential to account for clustering of patients within trials [42]. A separate adjustment term 
(𝛽2𝑖) is also ideally preferred, as the effect of the covariate may also differ across trials; 
however, this also increases the number of parameters to estimate and so, when there are non-
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convergence issues, it may be necessary to make a stronger assumption that this adjustment 
term is the same in each trial. 
 
We could also allow for residual heterogeneity in the treatment effect (i.e. not explained by 
the interaction term), in a random-effects model:: 
 𝜆𝑖𝑗(𝑡) = 𝜆0𝑗(𝑡)exp⁡(𝛽1𝑗𝑧𝑖𝑗 + 𝛽2𝑖𝑥𝑖𝑗 + 𝛽𝑇𝑥𝑖𝑗𝑧𝑖𝑗) 
𝛽1𝑗 = 𝛽1 + 𝑏1𝑗 
𝑏1𝑗~𝑁(0, 𝜏
2) 
(2) 
 
The coefficient 𝛽1 is now the average log hazard ratio for a distribution of possible treatment 
effects where 𝑥𝑖𝑗=0 and the random variable 𝑏1𝑗 follows a 𝑁(0, 𝜏
2) distribution, where 𝜏2⁡is 
the residual between-trial heterogeneity. One could also include a random effect on the 
interaction term.. 
 
2.2 Separating within-study and across-study interactions 
When we include the interaction as in (1) and (2), it amalgamates within and across-trial 
interactions. Alternatively, we can model these separately by centring the covariate 𝑥𝑖𝑗 about 
the mean, ?̅?𝑗 , in each trial j and also including the mean ?̅?𝑗 ⁡as an additional adjustment term to 
explain between-study heterogeneity. For example, if we assume there is no residual 
between-study heterogeneity in the treatment effect after including the covariate mean, ?̅?𝑗, 
then we can extend fixed-effect model (1): to  
 
 𝜆𝑖𝑗(𝑡) = 𝜆0𝑗(𝑡)exp⁡(𝛽1𝑗𝑧𝑖𝑗 + 𝛽2𝑖𝑥𝑖𝑗 + 𝛽𝑊(𝑥𝑖𝑗 − ?̅?𝑗)𝑧𝑖𝑗) 
𝛽1𝑗 = 𝛼 + 𝛽𝐴?̅?𝑗  
(3) 
Allowing for residual between-study heterogeneity, we can extend model (2) to 
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 𝜆𝑖𝑗(𝑡) = 𝜆0𝑗(𝑡)exp⁡(𝛽1𝑗𝑧𝑖𝑗 + 𝛽2𝑖𝑥𝑖𝑗 + 𝛽𝑊(𝑥𝑖𝑗 − ?̅?𝑗)𝑧𝑖𝑗) 
𝛽1𝑗 = 𝛼 + 𝛽𝐴?̅?𝑗 + 𝑏1𝑗 
𝑏1𝑗~𝑁(0, 𝜏
2) 
(4) 
 
Parameters in models (3) and (4) are as discussed before, but additionally the within trial 
coefficient, 𝛽𝑊, denotes the expected change in the treatment effect (log hazard rate ratio for 
individuals who receive the new treatment compared to control) for each one unit increase in 
𝑥𝑖𝑗, and the across-trial coefficient, 𝛽𝐴, denotes the expected change in the overall study 
treatment effect (log hazard rate ratio) for every one unit increase in⁡?̅?𝑗. 
 
Centering the patient-level covariate in models (3) and (4) ensures that 𝛽𝑊 now only explains 
within-study variability, and 𝛽𝐴 only explains between-study variability. In other words, the 
within- and the across-trial interaction estimates are now uncorrelated with each other and 
thus disentangled [9, 26]. In contrast, models (1) and (2) provide some weighted average of 
𝛽𝑊 and 𝛽𝐴, which will increase power but at the expense of potential ecological bias. Models 
(3) and (4) also allow one to estimate the magnitude of ecological bias by 𝛽𝑊 - 𝛽𝐴 [20], 
though there will usually be low power to identify, or statistically test, for ecological bias 
using this approach due to typically imprecise estimates of 𝛽𝐴. For researchers who prefer not 
to explain between-study heterogeneity, then model (4) can be fitted without the 𝛽𝐴?̅?𝑗 term, 
and the interpretation of 𝛽𝑊 would remain intact. 
 
2.3 Applicability of 𝜷𝑾 and 𝜷𝑨 
In this paper, the key focus is on providing interaction estimates that are meaningful to 
stratified (personalised) medicine, so that treatment decisions can be tailored to individuals 
based on their covariate values. For this reason, the main parameter of interest from the above 
models is 𝛽𝑊 because this explains differences in treatment response at the individual-level, 
and thus reduces within-trial (patient-level) variability. In contrast, 𝛽𝐴 explains differences in 
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population average treatment effects. Though this is helpful to reduce between-study 
variability, and perhaps to inform population-level comparisons (or predictions) of overall 
treatment effects (or overall prognosis [43]), it is potentially misleading to use 𝛽𝐴 to make 
inferences about individuals. This is demonstrated in detail in the simulations and examples 
in Sections 3 and 4, where we compare estimates for 𝛽𝑊 and 𝛽𝐴, and also their amalgamation 
(𝛽𝑇), in a range of settings.  
 
2.4 Model estimation 
To fit the stratified Cox regression for model (1) and (3), many standard statistical packages 
are available, such as coxph in R [44] and stcox in Stata [45], which maximise the profile 
likelihood. To estimate the random-effects models (2) and (4), a package such as coxme in R 
could be utilized, for example where the random-effects are integrated out to maximise the 
integrated partial likelihood [46]. Crowther et al. also show how to fit models (3) and (4) 
using Poisson regression with maximum likelihood via Gauss-Hermite quadrature [37], 
which has the advantage of also providing an estimate of the baseline hazards (one for each 
trial) if necessary (for example, for absolute risk predictions). 
 
3 Simulation study to evaluate treatment-covariate interactions 
We now describe two simulation studies to assess the performance of the models with 
merged (i.e. (1) or (2)) or separated interaction terms (i.e. (3) or (4)), when either ignoring 
((1) and (3)) or accounting for ((2) and (4)) residual between-study heterogeneity. In the first 
simulation study, we exclude any trial-level confounding factor (‘No confounding’ 
simulation study). In the second simulation study, we include a confounding factor 
(‘Confounding’ simulation study). In each simulation study, we consider binary (sex) or 
continuous (age) variables and their interaction with treatment. The survsim package in Stata 
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is utilized to simulate survival data [47], and the main steps of the simulation study are 
summarized as follows [48]: 
 
Step 1. Each simulated IPD meta-analysis dataset consists of J trials, with J fixed per 
simulation scenario. The number of patients in each trial was randomly determined by 
sampling from a normal distribution with mean N and standard error, N/5, where N is fixed 
per simulation scenario. 
 
Step 2. In each individual trial, each patient has an equal chance to be assigned to the 
experimental group zij=1 or the control group zij=0 by randomly sampling from a 
Bernoulli(0.5) distribution. 
 
Step 3a. If the covariate x is the binary variable, such as sex (1=Male, 0=Female), then for the 
ith patient in the jth trial, we firstly sample the mean of xj in the jth trial from a uniform 
distribution (0.5−V1, 0.5+V1) where V1 is chosen to be between 0 and 0.5 and then randomly 
sample xij for each patient in each study from a Bernoulli distribution with the obtained mean 
xj. 
 
If the covariate x is the continuous variable, age, then for the ith patient in the jth trial, the 
mean of xj in the jth trial is firstly sampled from a uniform distribution (50−V1, 50+ V1) where 
V1 is chosen to be between 0 and 35 and then xij is sampled from a normal distribution 
truncated at 15 and 85 with the obtained mean xj and a standard error V2, where V2 is chosen 
to be a positive number. V1 and V2 are fixed per simulations scenario. 
It is important to note that V1 defines the amount of across-trial variability in the mean 
covariate values, whereas V2 defines the amount of within-trial variability in the individual 
covariate values. If V1 is large then there is a greater spread of trial-level mean covariate 
values, and thus there is more opportunity (greater power) for any across-trials information to 
contribute in subsequent one-stage meta-analyses [7]. 
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Step 3b. In addition, for simulation scenarios with study-level confounding, we define yj to 
indicate whether the jth clinical trial has a higher dose of the treatment in the experimental 
arm (1=yes, 0=no). All trials with the mean of the binary covariate (sex) above 0.5 or the 
mean of continuous covariate (age) above 50 are given this extra effect β4 (yj = 1). 
 
Step 4. In each study separately, we use the survsim package in Stata to generate the patient-
level survival data (that is event times) for the ‘no confounding’ simulation study using (5) 
and the ‘confounding’ simulation study using (6), respectively: 
 
 𝜆𝑖𝑗(𝑡) = 𝜆0(𝑡)exp⁡(𝛽0𝑗 + 𝛽1𝑧𝑖𝑗 + 𝛽2𝑥𝑖𝑗 + 𝛽3𝑥𝑖𝑗𝑧𝑖𝑗) 
𝜆𝑖𝑗(𝑡) = 𝜆0(𝑡)exp⁡(𝛽0𝑗 + 𝛽1𝑧𝑖𝑗 + 𝛽2𝑥𝑖𝑗 + 𝛽3𝑥𝑖𝑗𝑧𝑖𝑗 + 𝛽4𝑦𝑗𝑧𝑖𝑗) 
(5) 
(6) 
 
where the baseline hazards within each trial are proportional to the same common hazard 
function 𝜆0(𝑡), which is taken to be the exponential distribution with mean of 0.1. The fixed 
term 𝛽0𝑗⁡for j=1,2,...,J represents the change in the baseline hazard (from the reference λ0(t)) 
for each trial, where 𝛽0𝑗  is sampled from a uniform distribution U(0,0.5) and 𝛽1, 𝛽2 and 𝛽3⁡are 
chosen to be fixed (the same for each trial) defining the treatment effect, adjustment factors 
and interaction respectively. In model (6), the additional fixed term 𝛽4⁡defines the 
confounding factor in the ‘confounding’ simulation, which is chosen to be a positive constant. 
Each simulated dataset censored patients at 5 years if the event had not previously occurred.  
 
Step 5. Step 1-Step 4 are repeated 1000 times to generate 1000 IPD meta-analysis datasets 
for each simulation scenario of interest. 
 
Step 6. To each 1000 meta-analysis datasets generated, we fit either fixed-effect or random-
effects models that either amalgamate within-trial and across-trial interactions (models (1) or 
(2)) or separate within-trial and across-trial interactions (models (3) or (4)). All models were 
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fitted using maximum likelihood estimation via coxme in R, and in agreement with how the 
data were generated, in all models we assumed that the covariate adjustment term was the 
same in each trial (i.e. that 𝛽2𝑖 = 𝛽2); this also reduced potential non-convergence issues. 
 
Then to evaluate and compare the 1000 achieved parameter estimates from the different types 
of models, we look at the mean bias, mean standard error, mean squared error, and coverage 
probability of 95% confidence intervals for each parameter estimate, with the performance of 
the estimates of the interaction terms of key interest for this article.  
 
Of key interest is whether models (1) to (4) provide good estimates of the parameter 𝛽3 from 
the data generating models (5) and (6). 𝛽3 is the difference in treatment effect between two 
individuals who differ in 𝑥𝑖𝑗 by one-unit, and is thus informative toward stratified 
(personalised) treatment decisions. Therefore, it is important than one-stage meta-analysis 
models (1) to (4) provide unbiased estimates of 𝛽3, and so the simulation results below focus 
on comparing the estimates of 𝛽𝑇, 𝛽𝑊 and 𝛽𝐴 from models (1) to (4) with the value of  𝛽3 
used to generate the IPD. 
 
3.1 Defining scenarios and parameter values  
The simulation study focused on four key scenarios: 
• ‘No confounding’ simulation study (model (5)): Binary variable (sex) 
• ‘No confounding’ simulation study (model (5)): Continuous variable (age). 
• ‘Confounding’ simulation study (model (6)): Binary variable (sex). 
• ‘Confounding’ simulation study (model (6)): Continuous variable (age) 
 
To generate the IPD meta-analysis datasets for each scenario, the above step by step process 
was used. To do this, we needed to define 𝛽1, 𝛽2 , 𝛽3⁡and 𝛽4 and chose positive values for 
ease of use. To consider a reasonably large treatment effect, 𝛽1 was set to be 1 (i.e. a hazard 
ratio of 2.72, indicating the treatment is beneficial for a situation where the outcome is good, 
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such as time to remission). 𝛽2 and 𝛽3 were defined to be 0.5 for the binary covariate (sex) and 
0.01 for the continuous covariate (age). 𝛽4⁡was essentially set to be 0 in the ‘no confounding’ 
simulation studies (as this parameter is not included in model (5)) and 0.75 in the 
‘confounding’ simulations. 
 
For each scenario, were also considered altering the number of trials and the number of 
observations per trial, that is, J=10 and N=500 for the ‘large’ setting, and J=5 and N=250 for 
the ‘small’ setting. To explore the association between the scale of the covariate x and 
interaction effects, we also varied V1 and V2: for the binary case, V1 was chosen to be 0.4 or 
0.2, and for the continuous case, V1 was set to be 20 or 10 and V2 was set to be 5 or 10. As 
mentioned above, as V1 increases the potential power of any across-trial information will also 
increase. This is likely to be especially important in situations where V1 is also large relative 
to V2 , such that the across-trial information is potentially larger than the within-study 
information [7]. 
 
In summary, our simulation study was repeated for each combination of V1, V2 and the 
sample size (J and N), for each of the ‘confounding’ and ‘no confounding’ situations, and for 
each of either a binary or a continuous covariate, and the results are now summarised below. 
 
3.2 Results 
3.2.1 Binary covariate, no trial-level confounding 
Consider first the ‘no confounding’ simulations with the binary covariate (sex). Since there is 
no study-level confounding, there is no unexplained heterogeneity across trials and so the 
random-effects models (2) and (4) are not considered here for brevity; however their findings 
were almost identical to those from models (1) and (3) 
A summary of the performance of the parameter estimates is shown in Table 1, for the 
different combinations of V1 and the sample size. In all settings the true interaction between 
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the log hazard ratio (treatment effect) and sex was 0.5, and so, if they reflected this, then the 
mean estimates of  𝛽𝑇, 𝛽𝑊 and 𝛽𝐴 should be 0.5.  
 
In all settings, ?̂?𝑇 from model (1) and ?̂?𝑊 and ?̂?𝐴 from model (3) were approximately 
unbiased estimates of the true treatment-sex interaction effect, and coverage probabilities of 
their 95% confidence intervals were also very close to 0.95. For model (3), the mean squared 
errors of ?̂?𝑊 were generally much smaller than those of⁡?̂?𝐴. This highlights that the within 
trial interaction term usually has greater power than its across-trial counterpart, and this 
difference becomes bigger as the sample size or V1 decreases. However, ?̂?𝑇 from model (1) 
has the smallest mean squared errors, as it is essentially a weighted combination of ?̂?𝑊 and 
?̂?𝐴 and therefore precision is improved, as indicated by the smaller standard deviations for ?̂?𝑇 
than ?̂?𝑊 and⁡?̂?𝐴. 
 Table 1: The estimates of the treatment-sex interaction effects in the simulations without trial level confounding. 
 Model (1) (amalgamated interaction) Model (3) (separated interactions) 
 
Size* 
V1 
Mean 
(s.d.) 
Bias 
MSE Coverage Mean (s.d.) 
Bias 
MSE Coverage 
𝛽𝑇 𝛽𝑇 𝛽𝑇 𝛽𝑇 𝛽𝑊 𝛽𝐴 𝛽𝑊 𝛽𝐴 𝛽𝑊 𝛽𝐴 𝛽𝑊 𝛽𝐴 
Large 0.4 
0.500 
(0.072) 
0 0.005 0.939 
0.500 
(0.082) 
0.500 
(0.164) 
0 0 0.007 0.027 0.945 0.957 
Large 0.2 
0.501 
(0.070) 
0.001 0.005 0.946 
0.502 
(0.071) 
0.490 
(0.335) 
0.002 -0.010 0.005 0.112 0.953 0.956 
Small 0.4 
0.494 
(0.143) 
-0.006 0.020 0.958 
0.492 
(0.153) 
0.517 
(0.484) 
-0.008 0.017 0.023 0.235 0.964 0.945 
Small 0.2 
0.505 
(0.138) 
0.005 0.019 0.953 
0.505 
(0.143) 
0.497 
(0.841) 
0.005 -0.003 0.020 0.707 0.948 0.959 
N.B. In all settings the true interaction between the log hazard ratio (treatment effect) and sex was 0.5, and so if, they reflected this, the 
mean estimates of  𝛽𝑇, 𝛽𝑊 and 𝛽𝐴 should be 0.5.  
MSE = mean-square error, and s.d. denotes standard deviation of the 1000 parameter estimates.  
* ‘Large’: J = 10 studies, N = 250 patients; ‘Small’: J = 5 studies, N = 250 patients.  
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3.2.2  Continuous covariate, no trial-level confounding 
Table 2Table 2 summarises the results for the continuous covariate (age) in the ‘no 
confounding’ scenarios. In all settings the true interaction between the log hazard ratio 
(treatment effect) and age was 0.01, and so, if they reflected this, the mean estimates of 𝛽𝑇, 
𝛽𝑊 and 𝛽𝐴 should be 0.01. The amalgamated effect, ?̂?𝑇 from model (1) and the within and 
across-trial effects, ?̂?𝑊 and ?̂?𝐴, from model (3) were generally unbiased as they were close to 
0.01 across all settings. The coverage in each setting was also very close to 0.95. As for the 
binary covariate, the amalgamated interaction ?̂?𝑇 generally performs best due to larger 
precision (smaller standard errors). 
 
In the scenarios with large sample size when using model (3), the standard error of the within 
and across-trial estimators were very similar, for example, see the cases for V1=10, V2=5 or 
V1=20, V2=10. However, when V1 was large relative to V2, the standard error of ?̂?𝑊 appeared 
slightly larger than⁡?̂?𝐴. For example, in the ‘large’ setting and V1=20 and V2=5, the standard 
deviation of ?̂?𝐴 was 0.006 whilst the standard deviation of ?̂?𝑊 was 0.003. Conversely, when 
V1 was small or similar relative to V2, the standard error of ?̂?𝑊 was smaller than⁡?̂?𝐴. For 
example, in the ‘large’ setting given V1=10 and V2=10, the standard deviation of ?̂?𝐴 was 
0.003 while ?̂?𝑊 was 0.007. 
 
These findings confirm previous work [7]: the power to detect the patient-level interaction 
effects using ?̂?𝑊 increases when V2 increases, and when using ?̂?𝐴 it increases when V1 
increases. For the simulations with small sample size, findings were similar except standard 
errors were of a larger magnitude throughout. 
 Table 2: The estimates of the treatment-age interaction effects in the simulations without trial level confounding. 
    Model (1) (amalgamated interaction) Model (3) (separated interactions) 
 
Size* 
V1 V2 
Mean 
(s.d.) 
Bias MSE Coverage Mean (s.d.) Bias MSE Coverage 
𝛽𝑇 𝛽𝑇 𝛽𝑇 𝛽𝑇 𝛽𝑊 𝛽𝐴 𝛽𝑊 𝛽𝐴 𝛽𝑊 𝛽𝐴 𝛽𝑊 𝛽𝐴 
Large 20 10 0.010 
(0.002) 
0 
<0.001 0.952 0.010 
(0.003) 
0.010 
(0.004) 
0 0 <0.001 <0.001 0.948 0.949 
Large 20 5 0.010 
(0.003) 
0 
<0.001 0.958 0.010 
(0.006) 
0.010 
(0.003) 
0 0 <0.001 <0.001 0.946 0.959 
Large 10 10 0.010 
(0.003) 
0 
<0.001 0.965 0.010 
(0.003) 
0.010 
(0.007) 
0 0 <0.001 <0.001 0.961 0.949 
Large 10 5 0.010 
(0.005) 
0 
<0.001 0.949 0.010 
(0.006) 
0.010 
(0.007) 
0 0 <0.001 <0.001 0.959 0.948 
Small 20 10 0.010 
(0.005) 
0 
<0.001 0.930 0.010 
(0.007) 
0.010 
(0.009) 
0 0 <0.001 <0.001 0.954 0.935 
Small 20 5 0.010 
(0.006) 
0 
<0.001 0.967 0.009 
(0.013) 
0.010 
(0.008) 
-0.001 0 <0.001 <0.001 0.953 0.960 
Small 10 10 0.010 
(0.006) 
0 
<0.001 0.945 0.010 
(0.007) 
0.011 
(0.018) 
0 0.001 <0.001 <0.001 0.947 0.953 
Small 10 5 0.010 
(0.010) 
0 
<0.001 0.949 0.010 
(0.013) 
0.010 
(0.018) 
0 0 <0.001 <0.001 0.949 0.952 
N.B. In all settings the true interaction between the log hazard ratio (treatment effect) and age was 0.01, and so, if they reflected this, the mean 
estimates of  𝛽𝑇, 𝛽𝑊 and 𝛽𝐴 should be 0.01. 
MSE = mean-square error, and s.d. denotes standard deviation of the 1000 parameter estimates.  
* ‘Large’: J = 10 studies, N = 250 patients; ‘Small’: J = 5 studies, N = 250 patients.  
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3.2.3  Binary covariate, trial-level confounding 
Consider now the situation of a binary covariate when there is unknown trial-level 
confounding (due to treatment dose, relating to yj in step 3(b) of the process used to simulate 
the IPD), and thus residual between-study heterogeneity. The simulation results are 
summarized in Table 3. 
 
Consider the fixed and random-effects models (3) and (4), which treated the within and 
across-trial interaction terms separately. The patient level interaction estimators,⁡?̂?𝑊, were 
still approximately unbiased for all settings as they were very close to the true value, 0.5. 
However, due to the unaccounted for trial-level confounder of dose in models (3) and (4), ?̂?𝐴 
was now biased in every setting. For example, given V1=0.2 and the ‘small’ sample setting, 
the mean of the ?̂?𝑊 was 0.502 from the random-effects model (3) and so close to the truth, 
whereas the mean of the across-trial interaction estimator, ?̂?𝐴, was 3.47 and so had serious 
upward bias. The stark difference between the estimators of ?̂?𝑊 and ?̂?𝐴 demonstrates the 
impact of ecological bias on ?̂?𝐴, due to the unaccounted trial-level confounder of dose. 
Interestingly, the bias in ?̂?𝐴 was not improved when using the random-effects model (4) 
rather than the fixed-effect model (3). There was also very poor MSE and coverage of ?̂?𝐴 due 
to the presence of ecological bias, whereas MSE was small and coverage acceptable for⁡?̂?𝑊. 
 
Models (1) and (2) also gave estimates of 𝛽𝑇 that were upwardly biased compared to 0.5. The 
random-effects model (2) performed better in terms of the coverage being closer to 0.95, but 
?̂?𝑇 was still upwards biased in most settings due to amalgamating the unbiased within trial 
interaction with the upwardly biased across-trial interaction. For example, given the ‘large’ 
setting and V1=0.4, the mean estimate of βT was 0.528 (coverage=0.927) for the random-
effects model and 0.721 (coverage=0.192) for the fixed-effect model, which are both above 
the true value of 0.5.  
 Table 3: The estimators of the treatment-sex interaction effects in the simulated data considering trial-level treatment confounding 
 
Size* V1 Model 
Mean (s.d.) Bias MSE Coverage 
Model 
Mean (s.d.) Bias MSE Coverage 
𝛽𝑇 𝜏 𝛽𝑇 𝛽𝑇 𝛽𝑇 𝛽𝑊 𝛽𝐴 𝜏 𝛽𝑊 𝛽𝐴 𝛽𝑊 𝛽𝐴 𝛽𝑊 𝛽𝐴 
Large 0.4 (1) 
0.721 
(0.091) 
 0.221 
0.057 0.192 (3) 
0.495 
(0.078) 
1.970 
(0.320) 
 -0.005 1.470 
0.006 2.263 0.944 0.003 
Large 0.4 (2) 
0.528 
(0.079) 
0.125 
(0.034) 
0.028 
0.007 0.927 (4) 
0.499 
(0.078) 
1.967 
(0.317) 
0.028 
(0.019) 
-0.001 1.467 
0.006 2.252 0.947 0.008 
Large 0.2 (1) 
0.599 
(0.076) 
 0.099 0.016 0.696 (3) 
0.496 
(0.071) 
3.400 
(0.638) 
 -0.004 2.900 0.005 8.816 0.943 0.000 
Large 0.2 (2) 
0.510 
(0.071) 
0.127 
(0.034) 
0.010 
0.005 0.947 (4) 
0.499 
(0.071) 
3.401 
(0.634) 
0.028 
(0.017) 
-0.001 2.901 
0.005 8.815 0.946 0.006 
Small 0.4 (1) 
0.694 
(0.176) 
 0.194 0.069 0.683 (3) 
0.490 
(0.162) 
1.977 
(0.749) 
 -0.010 1.477 0.026 2.741 0.949 0.107 
Small 0.4 (2) 
0.547 
(0.168) 
0.105 
(0.069) 
0.047 
0.03 0.934 (4) 
0.492 
(0.162) 
1.978 
(0.747) 
0.019 
(0.028) 
-0.008 1.478 
0.026 2.742 0.949 0.196 
Small 0.2 (1) 
0.597 
(0.139) 
 0.097 0.029 0.897 (3) 
0.501 
(0.135) 
3.463 
(1.543) 
 0.001 2.963 0.018 11.159 0.962 0.086 
Small 0.2 (2) 
0.524 
(0.136) 
0.111 
(0.065) 
0.024 
0.019 0.958 (4) 
0.502 
(0.136) 
3.470 
(1.537) 
0.018 
(0.027) 
0.002 2.970 
0.018 11.184 0.963 0.157 
N.B. In all settings the true interaction between the log hazard ratio (treatment effect) and sex was 0.5, and so, if they reflected this, the mean 
estimates of  𝛽𝑇, 𝛽𝑊 and 𝛽𝐴 should be 0.5.  
MSE = mean-square error, and s.d. denotes standard deviation of the 1000 parameter estimates.  
* ‘Large’: J = 10 studies, N = 250 patients; ‘Small’: J = 5 studies, N = 250 patients.  
.  
21 
In summary, the bias, MSE and standard error are vastly superior for ?̂?𝑊 in these settings, and there 
are serious issues with⁡?̂?𝐴. 
 
3.2.4 Continuous covariate, trial-level confounding 
The results for a continuous covariate in the setting of trial-level confounding are now summarized 
in Table 4. In all settings for both models (3) and (4), the mean and coverage of ?̂?𝑊 were close to 
0.01 and 0.95, respectively, indicating excellent performance of the within trial interaction. On the 
contrary, the ?̂?𝐴⁡estimates from the two models were upwardly biased with coverage much lower 
than 0.95, highlighting again the impact of ecological bias due to the omission of the trial-level 
confounder of dose used to generate the IPD in these settings (See step 3(b) of the simulation set-
up). 
 
When using models (1) and (2), the results show that ?̂?𝑇 also had poor performance in terms of bias 
and coverage, especially when the fixed-effect model (1) was utilized. Though the standard error of 
?̂?𝑇 was sometimes smaller than⁡?̂?𝑊, this only arose by utilizing the biased⁡?̂?𝐴. As noted elsewhere, 
the gain in standard error comes at the expense of bias and poorer coverage [12, 14, 23].  
  
 Table 4: The estimates of the treatment-age interaction effects in the simulated data considering trial-level treatment confounding. 
 
Size* V1 V2 Model 
Mean (s.d.) Bias MSE Coverage 
Model 
Mean (s.d.) Bias MSE Coverage 
𝛽𝑇  𝜏 𝛽𝑇 𝛽𝑇  𝛽𝑇  𝛽𝑊 𝛽𝐴 𝜏 𝛽𝑊 𝛽𝐴 𝛽𝑊 𝛽𝐴 𝛽𝑊 𝛽𝐴 
Large 20 10 (1) 
0.023 
(0.003) 
 0.013 <0.001 0.018 (3) 
0.010 
(0.003) 
0.040 
(0.006) 
 0 0.030 <0.001 0.001 0.958 0.003 
Large 20 10 (2) 
0.013 
(0.003) 
0.112 
(0.040) 
0.003 
<0.001 0.848 (4) 
0.010 
(0.003) 
0.041 
(0.006) 
0.027 
(0.019) 
0 0.031 
<0.001 0.001 0.958 0.010 
Large 20 5 (1) 
0.032 
(0.004) 
 0.022 <0.001 0.003 (3) 
0.010 
(0.006) 
0.039 
(0.006) 
 0 0.029 <0.001 0.001 0.965 0.002 
Large 20 5 (2) 
0.021 
(0.006) 
0.068 
(0.043) 
0.011 
<0.001 0.418 (4) 
0.010 
(0.006) 
0.039 
(0.006) 
0.025 
(0.018) 
0 0.029 
<0.001 0.001 0.964 0.005 
Large 10 10 (1) 
0.020 
(0.003) 
 0.010 <0.001 0.131 (3) 
0.010 
(0.003) 
0.068 
(0.012) 
 0 0.058 <0.001 0.003 0.949 0.003 
Large 10 10 (2) 
0.011 
(0.003) 
0.121 
(0.037) 
0.001 
<0.001 0.927 (4) 
0.010 
(0.003) 
0.068 
(0.012) 
0.026 
(0.018) 
0 0.058 
<0.001 0.004 0.946 0.005 
Large 10 5 (1) 
0.035 
(0.006) 
 0.025 0.001 0.018 (3) 
0.010 
(0.007) 
0.068 
(0.012) 
 0 0.058 <0.001 0.003 0.945 0.001 
Large 10 5 (2) 
0.015 
(0.007) 
0.109 
(0.041) 
0.005 
<0.001 0.826 (4) 
0.010 
(0.007) 
0.068 
(0.012) 
0.026 
(0.019) 
0 0.058 
<0.001 0.003 0.945 0.004 
Small 20 10 (1) 
0.022 
(0.007) 
 0.012 <0.001 0.38 (3) 
0.010 
(0.007) 
0.041 
(0.017) 
 0 0.031 <0.001 0.001 0.942 0.121 
Small 20 10 (2) 
0.015 
(0.008) 
0.085 
(0.078) 
0.005 
<0.001 0.778 (4) 
0.010 
(0.007) 
0.041 
(0.017 
0.015 
(0.026) 
0 0.031 
<0.001 0.001 0.943 0.184 
Small 20 5 (1) 
0.030 
(0.010) 
 0.020 0.001 0.173 (3) 
0.010 
(0.013) 
0.039 
(0.017) 
 0 0.029 <0.001 0.001 0.939 0.115 
Small 20 5 (2) 
0.024 
(0.012) 
0.050 
(0.073) 
0.014 
<0.001 0.464 (4) 
0.010 
(0.013) 
0.039 
(0.017) 
0.017 
(0.028) 
0 0.029 
<0.001 0.001 0.939 0.185 
Small 10 10 (1) 
0.019 
(0.007) 
 0.009 <0.001 0.665 (3) 
0.010 
(0.006) 
0.071 
(0.032) 
 0 0.061 <0.001 0.005 0.953 0.103 
Small 10 10 (2) 
0.012 
(0.007) 
0.106 
(0.069) 
0.002 
<0.001 0.917 (4) 
0.010 
(0.006) 
0.071 
(0.032) 
0.019 
(0.030) 
0 0.061 
<0.001 0.005 0.952 0.179 
Small 10 5 (1) 
0.032 
(0.012) 
 0.022 0.001 0.354 (3) 
0.009 
(0.013) 
0.069 
(0.031) 
 -0.001 0.059 <0.001 0.004 0.961 0.109 
 Small 10 5 (2) 
0.019 
(0.014) 
0.086 
(0.075) 
0.009 
<0.001 0.808 (4) 
0.009 
(0.013) 
0.069 
(0.031 
0.016 
(0.027) 
-0.001 0.059 
<0.001 0.004 0.961 0.185 
In all settings the true interaction between the log hazard ratio (treatment effect) and age was 0.01, and so, if they reflected this, the mean estimates 
of  𝛽𝑇, 𝛽𝑊 and 𝛽𝐴 should be 0.01. MSE = mean-square error, and s.d. denotes standard deviation of the 1000 parameter estimates.  
* ‘Large’: J = 10 studies, N = 250 patients; ‘Small’: J = 5 studies, N = 250 patients.  
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  Summary of simulation findings 
In conclusion, our simulation study has demonstrated that to understand how a patient-level 
covariate interacts with treatment effect, it is generally better to examine 𝛽𝑊 rather than 
either the trial-level interaction effect, 𝛽𝐴, or the amalgamated interaction effect 𝛽𝑇. Though 
?̂?𝑇 performs best when there is no trial-level confounding (due to larger precision and smaller 
MSE), its performance deteriorates considerably when trial-level confounding exists as its 
estimate and coverage are then severely affected by ecological bias, which may produce 
misleading conclusions. The magnitude of such bias is worse when using a fixed-effect 
model. Although it is still non-negligible in a random-effects model, the inclusion of residual 
between-trial heterogeneity reduces the power of the across-trial information, such that it has 
less weight toward ?̂?𝑇  than in a fixed-effect model. In contrast, the performance of ?̂?𝑊 
remains excellent in all situations considered, as it separates the within-trial information from 
the across-trial information. Finally, we note that an alternative two-stage approach to obtain 
the interaction estimate in each trial separately, followed by a traditional fixed-effect or 
random-effects model, gave almost identical results to those shown for ?̂?𝑊 from one-stage 
models (3) or (4). 
 
4 Application to an IPD meta-analysis in epilepsy 
Epilepsy is one of the most common neurological disorders threatening 65 million people 
throughout the world [49]. Previous researchers conducted an IPD meta-analysis of 1225 
patients from five randomized controlled trials to compare the effects of two antiepileptic 
drugs, Sodium Valproate (SV, drug=1) and Carbamazepine (CBZ, drug=0), when used as 
monotherapy in patients with partial onset seizures or generalized onset seizures [50-52]. 
Here we focus on the treatment effect (SV versus CBZ) on the outcome of time to 12 month 
remission, in relation to three patient-level covariates: age at randomisation (in years), type of 
epilepsy (generalized or partial) and the log number of seizures in 6 months before 
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randomisation. In a previous analysis of this data, Tudur Smith et al. examine interactions 
between the treatment effects and these three covariates [50] using one-stage models; 
however, these only had an amalgamated interaction term. Hence, here we examine if 
separation of within- and across-trial interaction alters the original conclusions. 
 
For each covariate separately, we used maximum likelihood (via the coxme module in R) to 
estimate models (1) and (2), which amalgamate within-trial and across-trial interactions, and 
models (3) and (4), which separate out within-trial and across-trial interactions. There were 
sometimes estimation problems when a separate covariate adjustment term was used in each 
trial, and so the results shown in Table 5 are from models (1) to (4) that assume 𝛽2𝑖 = 𝛽2, as 
this resolved any non-convergence during model estimation. In situations where convergence 
was possible with separate 𝛽2𝑖 terms, the results and conclusions were very similar to those 
shown. We also refitted all our models using the Poisson regression approach of Crowther et 
al.[37] and results were again very similar. We focus now only on the results for the 
interaction estimates (Table 5). As noted for the simulation study, an alternative two-stage 
approach gives almost identical results to those shown for ?̂?𝑊 from one-stage models (3) or 
(4).  
 
There was no evidence that either epilepsy type or the log number of seizures were modifiers 
of the treatment effect for any models (p>0.1). However, for both covariates the 
amalgamated estimator, ?̂?𝑇, was larger in absolute magnitude than the patient-level estimator, 
?̂?𝑊, suggesting that ecological bias may be present. For example, in the random-effects 
model for epilepsy type, ?̂?𝑇 was -0.09 (s.e.=0.156) and much larger than the ?̂?𝑊 value of -
0.025 (s.e.=0.058). This was due to ?̂?𝑇 being an amalgamation of ?̂?𝑊 with an extremely large 
?̂?𝐴=   -0.479 (s.e.=0.376). Interestingly, one of the five trials (Mattson) only had partial 
epilepsy type patients, and thus provides some across-trials information but no within-trial 
information toward this ?̂?𝑇.  
 The findings were even more dramatic for age, as statistical significance at the 5% level was 
different for ?̂?𝑇 and⁡?̂?𝑊. The within-trial effect,⁡?̂?𝑊, was not statistically significant (?̂?𝑊⁡⁡=      
-0.007, 95% CI: -0.019 to 0.005, p=0.219) whereas the amalgamated effect estimator was 
larger and statistically significant (?̂?𝑇= -0.011, 95% CI: -0.019 to -0.003) (p=0.004). Again, 
the difference arises due to ?̂?𝑇 amalgamating ?̂?𝑊 with⁡?̂?𝐴, which increases precision but at the 
expense of ?̂?𝐴 introducing potential ecological bias (study-level confounding), because  ?̂?𝑊 is 
about half the size of  ?̂?𝐴 (Table 5). 
 
The analysis of age was extended to replicate the original analysis of Tudur Smith et al., 
which included additional adjustment terms for epilepsy type and log number of seizures. The 
findings remained similar: the within-trial effect, ?̂?𝑊, was not statistically significant         
(?̂?𝑊= -0.006, 95% CI: -0.017 to 0.005, p=0.298), whereas the amalgamated effect estimate 
was statistically significant (?̂?𝑇=-0.008, 95% CI: -0.016 to -0.001) (p=0.024). Thus, based on 
the within-trial interaction alone, there is not strong evidence that age is a moderator of 
treatment effect and further research is recommended, which adds new insight on previous 
analyses of this data [50-52].  
 Table 5: Summary of the treatment-covariate effect estimates in the epilepsy data for the outcome of time to 12 months remission 
Covariate 
Model 
?̂?𝑻 
(s.e.) 
CI of ?̂?𝑻 Model 
?̂?𝑾 
(s.e.) 
?̂?𝑨 
(s.e.) 
CI of ?̂?𝑾 CI of ?̂?𝑨 
Age at 
randomisation  
(1) 
-0.011* 
(0.004) 
-0.019 to -0.003 (3) 
-0.007 
(0.006) 
-0.013* 
(0.005) 
-0.019 to 0.005 -0.023 to -0.003 
(2) 
-0.011* 
(0.004) 
-0.019 to -0.003 (4) 
-0.007 
(0.006) 
-0.013∗ 
(0.005) 
-0.019 to 0.005 -0.023 to -0.003 
Epilepsy type 
(1) 
-0.128 
(0.147) 
-0.416 to 0.160 (3) 
-0.026 
(0.168) 
-0.467 
(0.307) 
-0.355 to 0.303 -1.069 to 0.135 
(2) 
-0.090 
(0.156) 
-0.396 to 0.216 (4) 
-0.025 
(0.168) 
-0.479 
(0.376) 
-0.354 to 0.304 -1.216 to 0.258 
Log number of 
seizures 
(1) 
-0.025 
(0.056) 
-0.135 to 0.085 (3) 
-0.014 
(0.058) 
-0.100 
(0.122) 
-0.128 to 0.100 -0.339 to 0.139 
(2) 
-0.020 
(0.057) 
-0.132 to 0.092 (4) 
-0.013 
(0.058) 
-0.105 
(0.142) 
-0.127 to 0.101 -0.383 to 0.173 
s.e., standard error of the parameter estimate; * P-value<0.01. 
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5 Discussion 
IPD meta-analyses are increasingly prominent for time-to-event data, as the availability of 
IPD often allows a longer follow-up time and more sophisticated modelling than an AD 
meta-analysis. In particular, IPD meta-analyses of cancer studies are usually time-to-event, 
and there is enormous interest in their use for examining whether biomarkers are treatment 
effect modifiers to inform precision oncology [53] and for deriving absolute risk prediction 
models [40]. One-stage IPD models are often preferred, as this produces all meta-analysis 
results in a single analysis and is potentially more flexible, for example in regard modelling 
the baseline hazard, non-proportional hazards and non-linear trends, than a two-stage 
approach. It is therefore critical that researchers use the correct one-stage IPD modelling 
approach. 
 
In this article we compared, through simulations and an applied example, different 
specifications of a one-stage IPD meta-analysis model of time-to-event data where the goal is 
to estimate a treatment-covariate interaction. Our findings agree with previous work and 
simulations for continuous and binary outcomes [9, 23]: it is crucial to separate out within- 
and across-trial interactions, to avoid ecological bias caused by unexplained trial-level 
confounding [8, 54, 55]. Otherwise, clinical conclusions about interactions may be driven by 
ecological, trial-level information rather than solely within-trial information at the individual-
level. This is especially important when the power of any across-trial information is 
comparable to that for within-trial information, which occurs when the variation across-trials 
in the mean covariate values is similar to, or bigger than, the variation in individual covariate 
values[7].  The consequences of amalgamating within-trial and across-trial interactions may 
be substantial with false predictors of treatment effect being wrongly identified as important, 
or conversely genuine predictors of treatment effect being missed or discarded prematurely 
[1]. Our epilepsy example demonstrates how the magnitude of treatment effect modification 
for age and its statistical significance depends heavily on whether within-trial associations are 
29 
amalgamated or separated from across-trial associations; in particular, separating within-trial 
and across-trial information leads to less dramatic clinical and statistical conclusions.  
 
Though our simulations show that amalgamating within-trial and across-trial associations can 
improve precision of treatment-covariate interactions, this is not an adequate justification for 
doing so given the clear, adverse consequences on bias and coverage when trial-level 
confounding exists. In our opinion, gain in precision must not be made at the expense of 
potential bias and poor coverage. In situations of trial-level confounding, our simulations 
show that bias and inappropriate coverage of the amalgamated interaction occur regardless of 
whether it is estimated in a fixed-effect or random-effects setting, though the impact is far 
worse when using fixed-effect models. 
 
Simmonds et al. reviewed a sample of IPD meta-analyses of randomised trials published from 
2008 to 2014 [30], and state that: “In one-stage analyses, most papers reported including 
covariates in the one-stage regression model (21 reviews), although exactly how this was 
done was rarely reported.” This is concerning, as we would expect IPD publications to state 
that ecological bias was avoided by separating out within-trial and across-trial interactions, if 
indeed it had been done; hence, the absence of such reporting suggests interactions were 
(perhaps unknowingly) based on amalgamating within-trial and across-trial associations. 
Further empirical evidence would be welcome.  
 
Our recommendation to focus only on 𝛽𝑊 echoes previous calls by Thompson and 
colleagues, who state that “within-study and between-study information for interactions need 
to be distinguished” [14] and “in general, we would suggest that the estimated relations 
between the extent of treatment benefit and patients’ characteristics are derived only from 
within-trial information, so that confounding because of differences across trials is avoided” 
[4]. In situations where IPD are limited and most information comes from across trials (for 
example, when IPD are not available for all studies [9, 20, 23] or the variation in particular 
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covariate values within trials is small or even zero), again this does not provide credence for 
making recommendations based on the trial-level information due to the aforementioned 
issues. At best, meta-regression analyses using the trial-level should only be viewed as 
exploratory when the aim is to identify individual-level associations, and should not inform 
clinical recommendations. However, we recognise that others may not agree with these 
recommendations; for example, models have been proposed for combining across-study and 
within-study interactions when a mixture of IPD and aggregate data are available [56, 57].  
 
In our simulations we did not consider the extra complexity of potential confounding within-
trials when examining whether a particular factor interacts with treatment. Further, even 
when the analysis of a particular factor produces a 𝛽𝑊 that is statistically and clinical 
important, there may still be debate about whether the factor is a genuine causal modifier of 
treatment effect. Sun et al.[58] provide guidance for identifying whether differences in 
subgroups are believable, and this includes consideration of biological plausibility. 
If one is interested in the overall effect for particular subgroups (e.g. males and females), then 
a separate one-stage model could be fitted for each (thus avoiding interaction terms). 
However, before making statements about differences between subgroups, it is crucial to test 
/ quantify their difference using ?̂?𝑊, for which our one-stage models that separate out within-
trial and across-trial interactions are needed. Of course, a traditional two-stage meta-analysis 
of interaction estimates would also avoid ecological bias, and in most situations will give a 
summary meta-analysis result very similar to ?̂?𝑊  from our one-stage models that separate 
within-trial and across-trial interactions. However, especially in situations with small 
numbers of events, the more exact likelihood for the one-stage approach may give better 
statistical properties than the two-stage approach, for which the assumption of normally 
distributed estimates and known within-study variances may be inappropriate [16]. 
Ecological bias may also affect a two-stage approach where the interactions are jointly 
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synthesised with other parameter estimates (such as intercepts); for further discussion, see 
Riley et al.[59].  
 
In conclusion, where one-stage models are to be used to examine potential treatment-
covariate interaction, researchers should pre-specify in their protocol that they will separate 
out within-trial and across-trial interactions. Furthermore, recommendations about predictors 
of differential treatment effect should only be based on within-trial interactions, to avoid 
potentially erroneous implications for clinical practice that can arise when within-trial and 
across-trial information is amalgamated. 
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Supplementary material: Full epilepsy example results 
 
 
Outcome Covariate Model 
Parameter Estimate (s.e.) Model Parameter Estimate (s.e.) 
Βdrug βcov βT τ  Βdrug βcov βW βA τ 
Time to 12 month 
remission 
Age at randomisation  
(1) 
(2) 
0.199 
(0.129) 
0.199 
(0.129) 
0.008 
(0.003) 
0.008∗∗ 
(0.003) 
-0.011∗∗∗ 
(0.004) 
-0.011∗∗∗ 
(0.004) 
0.004 (3) 
(4) 
0.269∗ 
(0.158) 
0.269∗ 
(0.158) 
0.006 
(0.004) 
0.006 
(0.004) 
-0.007 
(0.006) 
-0.007 
(0.006) 
-0.013∗∗∗ 
(0.005) 
-0.013∗∗∗ 
(0.005) 
0.004 
Epilepsy type 
(1) -0.035 
(0.113) 
-0.238∗∗ 
(0.110) 
-0.128 
(0.147) 
 (3) 0.168 
(0.197) 
-0.287∗∗ 
(0.118) 
-0.026 
(0.168) 
-0.467 
(0.307) 
 
(2) -0.039 
(0.132) 
-0.256∗∗ 
(0.113) 
-0.090 
(0.156) 
0.136 
(4) 
0.186 
(0.239) 
-0.287∗∗ 
(0.118) 
-0.025 
(0.168) 
-0.479 
(0.376) 
0.106 
Log number of seizures 
(1) 
(2) 
-0.037 
(0.121) 
-0.030 
(0.131) 
-0.166∗∗∗ 
(0.040) 
-0.168∗∗∗ 
(0.040) 
-0.025 
(0.056) 
-0.020 
(0.057) 
0.104 
(3) 
(4) 
0.112 
(0.245) 
0.134 
(0.285) 
-0.171∗∗∗ 
(0.041) 
-0.171∗∗∗ 
(0.041) 
-0.014 
(0.058) 
-0.013 
(0.058) 
-0.100 
(0.122) 
-0.105 
(0.142) 
0.096 
N.B. * for P-value< 0.1, ** for P-value< 0.05 and *** for P-value<0.01
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